Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ozanimod (RPC-1063) 是一种选择性S1P1和S1P5受体激动剂,在[35S]-GTPγS 结合实验中,EC50分别为 410 pM 和 11 nM。它可研究治疗克罗恩病、溃疡性结肠炎、多发性硬化症和复发性多发性硬化症的试验。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 433 | 现货 | ||
5 mg | ¥ 957 | 现货 | ||
10 mg | ¥ 1,490 | 现货 | ||
25 mg | ¥ 2,970 | 现货 | ||
50 mg | ¥ 4,550 | 现货 | ||
100 mg | ¥ 6,480 | 现货 | ||
200 mg | ¥ 8,850 | 现货 | ||
500 mg | ¥ 12,900 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,090 | 现货 |
产品描述 | Ozanimod (RPC-1063) (RPC1063) is a specific oral S1P Receptor 1 modulator. Ozanimod has been used in trials studying the treatment of Crohn's Disease, Ulcerative Colitis, Multiple Sclerosis, and Relapsing Multiple Sclerosis. |
靶点活性 | S1P5R:11 nM(EC50), S1P1R:0.41 nM(EC50) |
体外活性 | In S1P1R-HEK293T cells, Ozanimod induces sustained S1P1R internalization and degradation. [1] |
体内活性 | In vivo, Ozanimod shows high oral bioavailability and volume of distribution. In a MOG-induced EAE mouse model, Ozanimod (3 mg/kg, p.o.) suppresses Clinicalal symptoms. In a rat TNBS model of inflammatory bowel disease, Ozanimod (1.2 mg/kg, p.o.) inhibits Clinicalal and histological disease scores. In a Na?ve CD4+CD45Rbhi T cell adoptive transfer model, Ozanimod (1.2 mg/kg, p.o.) also significantly reduced disease severity as assessed by measuring the degree of inflammation, gland loss, hyperplasia, neutrophil infiltrate and mucosal thickness. [1] |
别名 | 奥扎莫德, RPC-1063 |
分子量 | 404.46 |
分子式 | C23H24N4O3 |
CAS No. | 1306760-87-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 75 mg/mL (185.4 mM)
Ethanol: 10 mg/mL (24.72 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol | 1 mM | 2.4724 mL | 12.3622 mL | 24.7243 mL | 61.8108 mL |
5 mM | 0.4945 mL | 2.4724 mL | 4.9449 mL | 12.3622 mL | |
10 mM | 0.2472 mL | 1.2362 mL | 2.4724 mL | 6.1811 mL | |
20 mM | 0.1236 mL | 0.6181 mL | 1.2362 mL | 3.0905 mL | |
DMSO | 50 mM | 0.0494 mL | 0.2472 mL | 0.4945 mL | 1.2362 mL |
100 mM | 0.0247 mL | 0.1236 mL | 0.2472 mL | 0.6181 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Ozanimod 1306760-87-1 GPCR/G Protein S1P Receptor LPL Receptor 奥扎莫德 RPC1063 RPC 1063 neurosurgery sphingosine 1-phosphate (S1P) inhibit Lysophospholipid Receptor Inhibitor multiple sclerosis (MS) RPC-1063 S1P receptor subtypes 5 (S1P5) S1P receptor subtypes 1 (S1P1) inhibitor